RecruitingPhase 3NCT06312176
Rare condition
Autosomal dominant multiple pterygium syndrome
101
studies recruiting now
as of 7 Sept 2026
607
studies registered in total
as of 7 Sept 2026
46
countries with a recruiting site
as of 7 Sept 2026
14 Oct 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 3NCT06989112
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RecruitingPhase 3NCT07216703
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
RecruitingPhase 3NCT06170788
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
RecruitingPhase 1 / Phase 2NCT06445972
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 101 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
ArgentinaAustraliaAustriaBelgiumBrazilCanadaChileChinaColombiaCosta RicaCzechiaDenmarkFinlandFranceGermanyGreeceHong KongHungaryIndiaIrelandIsraelItalyJapanMalaysiaMexicoNetherlandsNew ZealandNorwayPeruPhilippinesPolandPortugalPuerto RicoRomaniaSingaporeSouth AfricaSouth KoreaSpainSwedenSwitzerlandTaiwanThailandTurkey (Türkiye)United KingdomUnited StatesVietnam
Keep watching
Get an email when a new Autosomal dominant multiple pterygium syndrome study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Autosomal dominant multiple pterygium syndrome
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (MYH3).
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).